Wheel NEW OEM Hub 3F1Z1130AA Taurus Ford 00-07 Silver Sparkle (2) Set Cap Center Other Car & Truck Exterior Parts


  1. Home
  2. Wheel NEW OEM Hub 3F1Z1130AA Taurus Ford 00-07 Silver Sparkle (2) Set Cap Center
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
OEM NEW Wheel Hub Center Cap Set (2) Sparkle Silver 00-07 Ford Taurus 3F1Z1130AA
Condition: New Year: 2002 2003 2004 2005 2006 2007
Make: Ford Model:

Taurus

Manufacturer Part Number:

3F1Z-1130-AA

Bundle Listing: Yes
Placement on Vehicle: Left, Right, Front, Rear Fitment Type: Direct Replacement
Other Part Number: 3F1Z1130AA (2) Modified Item: No
Brand:

Ford

Custom Bundle: Yes
Non-Domestic Product: No Interchange Part Number: 3F1Z*1130*AA (x2)
Warranty: 2 Year Color:

Sparkle Silver

Bundle Description: 3F1Z*1130*AA (x2) UPC:

Does not apply






published on tue nov 09 2021

Wheel NEW OEM Hub 3F1Z1130AA Taurus Ford 00-07 Silver Sparkle (2) Set Cap Center Other Car & Truck Exterior Parts

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Wheel NEW OEM Hub 3F1Z1130AA Taurus Ford 00-07 Silver Sparkle (2) Set Cap Center Other Car & Truck Exterior Parts

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS